Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02155205 · ClinicalTrials.gov registry record · Phase 1

A Thorough QT Study of Telotristat Etiprate

A Phase 1 study, sponsored by Lexicon Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target

NCT02155205 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 48 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02155205, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

The purpose of this study is to demonstrate that telotristat etiprate does not differ from placebo in the mean change from Baseline QT interval corrected for heart rate.

Interventions

  • DRUG Placebo
  • DRUG Moxifloxacin
  • DRUG Telotristat etiprate

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2014-05
Phase Phase 1

Sponsor

Lexicon Pharmaceuticals

56 total trials

What the Registry Record Tells You About NCT02155205

The ClinicalTrials.gov registry entry for NCT02155205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02155205 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02155205 about?

NCT02155205 is a clinical study titled "A Thorough QT Study of Telotristat Etiprate". The purpose of this study is to demonstrate that telotristat etiprate does not differ from placebo in the mean change from Baseline QT interval corrected for heart rate.

What is the current status of trial NCT02155205?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2014-05.

What interventions are being tested in trial NCT02155205?

The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Telotristat etiprate (DRUG).

Who is sponsoring clinical trial NCT02155205?

This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.